1-4 of 4
Paul Stockman
Close
Sort by
Journal Articles

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

Clinical Trials & Observations
Bob Löwenberg, Petra Muus, Gert Ossenkoppele, Philippe Rousselot, Jean-Yves Cahn, Norbert Ifrah, Giovanni Martinelli, Sergio Amadori, Ellin Berman, Pieter Sonneveld, Mojca Jongen-Lavrencic, Sophie Rigaudeau, Paul Stockman, Alison Goudie, Stefan Faderl, Elias Jabbour, Hagop Kantarjian
Journal: Blood
Blood (2011) 118 (23): 6030–6036.
https://doi.org/10.1182/blood-2011-07-366930
Published: 2011
Journal Articles

Phase I Study of the Aurora B Kinase Inhibitor Barasertib (AZD1152) to Assess the Pharmacokinetics (PK), Metabolism and Excretion in Patients (pts) with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Mike Dennis, MD, MRCP, FRCPath, Michelle Davies, RGN, BN, Stuart Oliver, MD, Roy D'Souza, BSc (Hons), Laura Pike, MSc, Paul Stockman, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2602.
https://doi.org/10.1182/blood.V118.21.2602.2602
Published: 2011
Journal Articles

Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, MD, Mikkael A. Sekeres, MD, MS, Vincent Ribrag, MD, Philippe Rousselot, MD, PhD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Kate Owen, MBChB, Paul Stockman, MD, PhD, Stuart Oliver, MFPM
Journal: Blood
Blood (2010) 116 (21): 656.
https://doi.org/10.1182/blood.V116.21.656.656
Published: 2010
Journal Articles

Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.

Bob Lowenberg, MD, PhD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, Alison Goudie, Paul Stockman, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 2080.
https://doi.org/10.1182/blood.V114.22.2080.2080
Published: 2009